{"id":801532,"date":"2025-01-16T08:09:10","date_gmt":"2025-01-16T13:09:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/"},"modified":"2025-01-16T08:09:10","modified_gmt":"2025-01-16T13:09:10","slug":"enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/","title":{"rendered":"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)"},"content":{"rendered":"
\n

ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) — Africa CDC\u2019s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo (DRC). These patients have been randomized in this pivotal clinical trial, marking a critical step in addressing the Mpox health threat. As Clade Ib cases emerge outside Africa and Clade I and II cases continue to be reported across the continent, Africa CDC, INRB, and PANTHER are leading efforts to test promising therapeutic options to combat this persistent health threat.<\/p>\n

Declared a Public Health Emergency of Continental Security on August 13, 2024, Mpox remains a significant health threat across Africa, particularly among vulnerable populations such as women, children, and individuals living with HIV. Despite the pressing need, no therapeutic has been approved to treat Mpox in the United States or Africa. Recent results from the PALM 007 and STOMP studies showed that tecovirimat did not show the expected effect on lesion resolution, underscoring the need for additional therapeutic options.<\/p>\n

The MOSA trial demonstrates Africa\u2019s leadership in addressing this urgent healthcare gap. The study will evaluate different antivirals, either alone or in combination. It will start by evaluating the safety and efficacy of brincidofovir. Brincidofovir is an antiviral from the global life sciences company Emergent BioSolutions. In the United States it is available under a single-patient emergency use Investigational New Drug (IND) for Mpox. The safety and efficacy of brincidofovir to treat Mpox in humans has not been established in double-blind, placebo-controlled studies for Mpox. In the MpOx Study, patients will receive either brincidofovir or a matching placebo in a liquid oral formulation, administered once-a-week, for 2 weeks.\u00a0<\/p>\n

A first interim analysis is expected by the end of Q1 2025.<\/p>\n

\u201cAfrica is not just responding to the Mpox outbreak; we are leading the charge in finding solutions by spearheading research and development for Mpox therapeutics,\u201d said Africa CDC Director General, Dr. Jean Kaseya. \u201cThe MpOx Study represents a groundbreaking step toward developing a treatment. This effort goes beyond research\u2014it\u2019s about African ownership and leadership in addressing our continent’s health challenges through vital, innovative research.\u201d<\/p>\n

Sponsored by PANTHER, a key research partner of Africa CDC, the MOSA trial builds upon initial funding provided by the European Union\u2019s Horizon Europe program. The study protocol was reviewed through the AVAREF collaborative process in 2023, ensuring it meets the highest ethical and scientific standards. The innovative study design includes pre-planned interim analyses, allowing for rapid decision-making should early signs of either futility or success be observed.<\/p>\n

\u201cThis milestone highlights the vital role of research preparedness and response. Funded initially by Horizon Europe as part of the emergency response to the mpox outbreak in 2022, I am delighted to see MOSA trial fully operational now to advance treatments for mpox.\u201d Marc Lema\u00eetre, European Commission, Director-General for Research and Innovation.<\/p>\n

\u201cWe are proud of this important milestone illustrating PANTHER\u2019s mission in addressing continental epidemic priorities,\u201d said Prof. Samba Ousmane Sow, Director General of the Centre for Vaccine Development in Mali (CVD-Mali) and President of the Board of PANTHER. \u201cWe hope to contribute to Africa CDC\u2019s response to the current crisis while also deriving concrete lessons to better prepare for future ones.\u201d<\/p>\n

As Africa continues to report rising Mpox cases, particularly in the DRC, the MOSA trial seeks to provide critical data on potential treatment options. The study will recruit both children and adults, focusing on those most at risk of severe outcomes, especially in remote areas.<\/p>\n

\u201cWe look forward to advancing MOSA, another critical research project that complements ongoing studies on transmission, vaccines and social sciences,\u201d said Prof Placide Mbala, Principal Investigator for the study in the DRC and Head of the Department of Epidemiology and Global Health at INRB.<\/p>\n

\u201cMpox continues to be a global threat to public health, creating a need for treatments and vaccines,\u201d said Simon Lowry, M.D., chief medical officer, head of research and development, Emergent. \u201cWe applaud Africa CDC and PANTHER for their work progressing the \u2018MpOx Study in Africa\u2019 (MOSA) and advancing research for brincidofovir.\u201d\u00a0<\/p>\n

The U.S. FDA Prescribing Information for TEMBEXA\u00ae (brincidofovir) is provided for additional safety information here<\/a>.\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/p>\n

\n About the <\/strong>
\n Pandemic Preparedness Platform for Health and Emerging Infections Response<\/strong>
\n (PANTHER)<\/strong>\n <\/p>\n

PANTHER is the first African-led pandemic preparedness platform for health and emerging infection response. Bringing together leading African and global researchers and public health teams, it aims to create regional hubs and clinical research platforms to support preparedness and rapid response to emerging infectious diseases globally, particularly in Africa.
For more information, visit https:\/\/pantherhealth.org.<\/u><\/a><\/p>\n

PANTHER is sponsoring MOSA as part of the MPX-RESPONSE Project that has received funding from the European Union\u2019s Horizon Europe Research and Innovation programme under grant agreement 101115188<\/p>\n

\n \n <\/p>\n

\n About Africa Centres for Disease Control and Prevention (Africa CDC)<\/strong>
\n
The Africa Centres for Disease Control and Prevention (Africa CDC) is a public health agency of the African Union. It is autonomous and supports member states in strengthening health systems. It also helps improve disease surveillance, emergency response, and disease control.<\/p>\n

Learn more at: http:\/\/www.africacdc.org<\/u><\/a> and connect with us on LinkedIn<\/u><\/a>, Twitter<\/u><\/a>, Facebook<\/u><\/a>\u00a0and YouTube<\/u><\/a>.\u00a0\u00a0<\/p>\n

\n About\u202fEmergent BioSolutions<\/strong>\n <\/p>\n

At Emergent, our mission is to protect and enhance life. For over 25 years, we\u2019ve been at work defending people from things we hope will never happen\u2014so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we help protect public health, visit our\u202fwebsite<\/a>\u202fand follow us on\u202fLinkedIn<\/a>,\u202fX<\/a>,\u202fInstagram<\/a>,\u202fApple Podcasts<\/a>\u202fand\u202fSpotify<\/a>.<\/p>\n

\n Media Contacts:<\/strong>\n <\/p>\n

\n Margaret Edwin<\/strong> | Director of Communication and Public Information | Africa CDC EdwinM@africacdc.org<\/u><\/a><\/p>\n

\n Jessica Ilunga <\/strong>| Communication Officer | PANTHER
Email: Media@pantherhealth.org<\/u><\/a>
<\/a><\/u>Website: www.pantherhealth.org<\/u><\/a>
<\/a><\/u>Twitter<\/u><\/a> | LinkedIn<\/u><\/a><\/p>\n

\n Assal Hellmer<\/strong> | Vice President, Communications | Emergent BioSolutions
Email: mediarelations@ebsi.com<\/a><\/p>\n

A photo accompanying this announcement is available at https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/683aea7c-60d3-4af9-8964-1d0031f84727<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) — Africa CDC\u2019s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo (DRC). These patients have been randomized in this pivotal clinical trial, marking a critical step in addressing the Mpox health threat. As Clade Ib cases emerge outside Africa and Clade I and II cases continue to be reported across the continent, Africa CDC, INRB, and PANTHER are leading efforts to test promising therapeutic options to combat this persistent health threat. … <\/p>\n

Continue reading “Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-801532","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) — Africa CDC\u2019s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo (DRC). These patients have been randomized in this pivotal clinical trial, marking a critical step in addressing the Mpox health threat. As Clade Ib cases emerge outside Africa and Clade I and II cases continue to be reported across the continent, Africa CDC, INRB, and PANTHER are leading efforts to test promising therapeutic options to combat this persistent health threat. … Continue reading "Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-16T13:09:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkxMCM2Njk2ODE5IzIwMTA4NjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)\",\"datePublished\":\"2025-01-16T13:09:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/\"},\"wordCount\":1063,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjkxMCM2Njk2ODE5IzIwMTA4NjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/\",\"name\":\"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjkxMCM2Njk2ODE5IzIwMTA4NjY=\",\"datePublished\":\"2025-01-16T13:09:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjkxMCM2Njk2ODE5IzIwMTA4NjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzMjkxMCM2Njk2ODE5IzIwMTA4NjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/","og_locale":"en_US","og_type":"article","og_title":"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) - Market Newsdesk","og_description":"ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) — Africa CDC\u2019s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has enabled the enrollment of the first patients at Mbandaka Hospital in Equateur Province, Democratic Republic of Congo (DRC). These patients have been randomized in this pivotal clinical trial, marking a critical step in addressing the Mpox health threat. As Clade Ib cases emerge outside Africa and Clade I and II cases continue to be reported across the continent, Africa CDC, INRB, and PANTHER are leading efforts to test promising therapeutic options to combat this persistent health threat. … Continue reading \"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-16T13:09:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkxMCM2Njk2ODE5IzIwMTA4NjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)","datePublished":"2025-01-16T13:09:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/"},"wordCount":1063,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkxMCM2Njk2ODE5IzIwMTA4NjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/","name":"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkxMCM2Njk2ODE5IzIwMTA4NjY=","datePublished":"2025-01-16T13:09:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkxMCM2Njk2ODE5IzIwMTA4NjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzMjkxMCM2Njk2ODE5IzIwMTA4NjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enrollment-starts-in-africa-cdc-led-mpox-therapeutic-study-mosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=801532"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/801532\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=801532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=801532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=801532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}